Q-omics provides the consensus-scored MUC17 profile across patient tissues and cancer cell-line models. MUC17 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MUC17 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, MUC17 mutation status shows 13,305 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight KICH, HNSC, and UCEC as cancer lineages where MUC17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC17 survival associations across molecular data types. MUC17 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC17 RNA expression–survival associations across cancer types. High MUC17 expression shows unfavorable associations in KICH, KIRC, UCS, LUAD and BRCA, but favorable associations in SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MUC17 RNA expression.
This table summarizes MUC17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MUC17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC17 shows lower tumor expression in THCA and higher tumor expression in HNSC, PAAD, STAD and KIRC. The HNSC box plot shows higher MUC17 RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .020).
This table shows molecular features associated with MUC17 in patient tissues and cancer cell lines. In patient samples, MUC17 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
